IL-23R — Drug Target
All drugs that target IL-23R — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Phase 2 pipeline (1)
- Any biologic treatment for psoriasis · Bristol-Myers Squibb · IL-23 inhibitor · Immunology
Tildrakizumab blocks the interaction between interleukin-23 (IL-23) and its receptor, reducing inflammation in the body.